DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Thill M, Schmidt M.
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.
Ther Adv Med Oncol 2018;
10: 1758835918793326
doi:10.1177/1758835918793326
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.